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a  b  s  t  r  a  c  t
The major medical/scientiﬁc research project of the past two decades is the human genome
project and its suggested clinical applications. The project can usefully be framed as a
quest to cure disease, especially cancer, and even to defy mortality. The hero of this quest
is  the project leader, who currently is trying, almost desperately, to “translate” the sci-
ence of the genome into public health practice (screening) and the practice of medicine,
often termed tailored, precision or “personalized medicine.” In America’s dysfunctional and
patchwork healthcare system, adding another layer of extremely expensive and (to date)
marginally effective screening procedures and genetics-based cancer treatments is a hard
sell.  Nonetheless, framing the human genome project as a quest for added life can make it
seem altogether normal, even natural, and can help rally the public to its support. A second,
parallel quest is the public health-political quest for a system that guarantees universal
access to healthcare for Americans. The ultimate success of this quest will depend not on
any  scientiﬁc or medical breakthrough, even a genetic one, but on political will. Creating
and sustaining political support for universal healthcare access will require, I suggest, the
deployment of stories of real Americans whose lives have been made much more  miserable
by  the lack of access to decent healthcare. These two quests are converging in ways that may
make them incompatible because of the extreme expense of personalized medicine, and, at
least  so far, its inability to add more than marginal beneﬁt to the lives of most Americans.
Nonetheless, until Americans are more comfortable accepting death, we will continue to
ﬁght our mortality with activities we frame as quests, making our dysfunctional healthcare
system less and less able to respond to the health needs of the American public.
©  2014 Escola Nacional de Saúde Pública. Published by Elsevier España, S.L.U. All rights
reserved.
Medicina  personalizada  ou  saúde  pública?  Bioética,  direitos  humanos  e
escolhaPalavras-chave:
Medicina personalizada
r  e  s  u  m  o
O Projecto do Genoma Humano (PGH) (Human Genome Project),  bem como as suas possíveis
aplicac¸ões clínicas, constituem o maior projecto de investigac¸ão biomédica das últimas duas
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décadas. Este Projecto pode ser descrito como uma jornada em busca da cura para a doenc¸a
(em termos gerais), para o cancro (em particular) e, em última análise, uma tentativa de
desaﬁar a nossa própria mortalidade. O herói desta jornada é o líder do Projecto, que, actual-
mente tenta, quase desesperadamente, “traduzir” a ciência do genoma para a prática em
saúde pública e em medicina, um esforc¸o que é denominado global e genericamente como
medicina personalizada. No contexto de um sistema de saúde disfuncional e incompleto
como o Americano, é difícil persuadir os cidadãos que é útil adoptarem-se tratamentos e
rastreios para o cancro baseados na genética, uma vez que estes são extremamente dis-
pendiosos e apenas (pelo menos à data), marginalmente eﬁcazes. Todavia, enquadrar o
PGH  como uma jornada em busca de mais tempo de vida pode conferir ao mesmo um cariz
de  normalidade (quase de naturalidade) que poderá ajudar a mobilizar o público em seu
redor. Uma segunda e paralela jornada, esta simultaneamente política e de saúde pública,
caracteriza-se pela procura de um sistema de saúde que garanta a todos os Americanos o
acesso universal a cuidados de saúde. Ora, o sucesso último desta procura dependerá não
de  uma  descoberta cientíﬁca ou biomédica, mesmo que esta provenha da área da genética,
mas  da existência de vontade política. Mais, criar e manter apoio político para o acesso uni-
versal à saúde requererá, sugiro, o recurso às histórias de vida dos Americanos reais, que
se  tornaram tão mais miseráveis pela falta de acesso a cuidados de saúde decentes. Estas
duas jornadas têm convergido de tal forma que, devido aos custos enormes da medicina
personalizada e, pelo menos até hoje, da sua incapacidade de conferir mais do que benefí-
cios  marginais à vida da maioria dos Americanos, elas se tornam hoje quase incompatíveis.
No  entanto, até que a América se torne mais confortável perante a aceitac¸ão da morte, con-
tinuaremos a combater a nossa mortalidade com actividades que melhor se caracterizam
como jornadas, ajudando a que o nosso sistema de saúde, já de si disfuncional, se torne
cada vez menos capaz de responder às necessidades de saúde dos Americanos.





















T“The new and rapidly evolving ﬁeld of genomics offers consider-
able possibilities for the improvement of human health.  . .but the
full extent of its possible hazards are not yet fully appreciated.”
World Health Organization, Genomics and World Health,  2002.
Modern medical research and mass marketing conspire
o enable Americans to deny death by suggesting that
esearchers may yet discover a medical “fountain of youth.”
ven if the fountain cannot enable immortality, the suggestion
s that it will at least be able to postpone death for a very long
ime. Medical progress itself is now measured almost exclu-
ively by longevity—in terms of both overall life expectancy,
ut also in terms of survival rates following treatment for
isease. Quantity of life continues to be relentlessly pursued
nd privileged over quality of life. The focus on increasing
ongevity in medical research is enabled, and even encour-
ged, by the arts—including classic story telling methods,
ncluding the use of the quest myth, and the creative use of
etaphor.1In this chapter I examine the application of the quest
yth and related metaphors to the most celebrated medical
esearch project of the past two decades, the human genome
1 Portions of this chapter are adapted from and continue the
xploration begun in Annas, GJ. Bioethics and genomics. In:
ndrew Clapham and Mary Robinson, editors. Realizing the right
o  health, Ruffer & Rub, 2009, and Annas GJ. The songs of spring:
uest myths, metaphors, and medical progress. In: Paul MacNeil,
he arts and ethics, Springer, 2013.project, and the ongoing attempt to “translate” genomics into
clinical medicine, commonly termed “personalized medicine,”
and/or public health. These two goals may, however, be incom-
patible. As James Evans and his colleagues put it in early 2013,
“Genomics and public health have been uneasy bedfellows for
some time.”1
Genomic  “personalized”  medicine
Personalized medicine, medicine tailor-made for each individ-
ual patient, has as its premise the belief that an individual’s
unique genome determines (at least probabilistically) the way
the individual will respond to speciﬁc drugs, diets, exercise
regimes, and other treatment or risk reduction strategies. The
goal is often stated as replacing “one size ﬁts all” medicine
with “the right drug, for the right patient, at the right time.”
This is a great oversimpliﬁcation. What is really at stake
is stratiﬁed medicine—treating people with similar genetic
proﬁles the same. The most prominent metaphor is to use
the individual’s DNA, the “blueprint of life,” to “tailor” treat-
ment regimes that are most likely to lead to successful
treatment—measured in increased length of life, sometimes
simply termed “saving lives.”2
The dream of personalized medicine is largely powered by
the successes of the personal computer and the smartphone.
Can technology do the same for genome testing by driving
down the price and improving the accuracy and speed? By
early 2013 the answer is maybe. As explained by an infor-
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mation technologist, “For all of human history, humans have
not had the readout of the software [the genome] that makes
them alive. Once you make the transition from a data poor to
a data rich environment, everything changes.”3 So there is a
parallel technological quest, as the New York Times suggested
in its headline for an article about new genome sequencing
machines, to “break the gene barrier.”4
This quest to cross the gene barrier, of course, immediately
suggests the successful quest to break the sound barrier, and
even the successful quest to put a man  on the moon. Pres-
ident Clinton announced the completion of the ﬁrst draft of
the human genome at a White House event featuring both
Francis Collins and Craig Venter in 2000.5 What has been most
commented on is the president’s comparison of the map  of the
American frontier that Meriwether Lewis prepared for Thomas
Jefferson, with the “map” of the human genome, which Pres-
ident Clinton termed “the most important, most wondrous
map  ever produced by human kind.” Perhaps he can be for-
given for his over-the-top rhetoric in referring to the code as
“the language in which God created life.” But Clinton also knew
what the public was likely to be interested in:
With this profound new knowledge, humankind is on the
verge of gaining immense new power to heal. Genome sci-
ence will have a real impact on all our lives and even more
on the lives of our children. It will revolutionize the diagnosis,
prevention and treatment of most, if not all, human diseases. In
coming years, doctors increasingly will be able to cure dis-
eases like Alzheimer’s, Parkinson’s, diabetes and cancer by
attacking their genetic roots. . .In fact, it is now conceivable
that our children’s children will know the term ‘cancer’ only as a
constellation of stars. (emphasis added)5
The precious prize at the end of this quest is the abolition
of disease. But when Clinton went off script at the end of the
press conference, he reverted to the (American) dream of a
longer life: “When we get all this worked out and we’re all liv-
ing to be 150. . .young people will still fall in love and old people
will still ﬁght about things that should have been resolved 50
years ago. . .” President Clinton can, of course, be forgiven for
speaking directly to the public and exaggerating the potential
payoff of his federal program. But Francis Collins, the leader of
the federal program (he prefers military metaphors, describ-
ing himself as the ‘ﬁeld marshall’ of the genome project) was
just as extravagant when talking about the project to scientists
assembled at Cold Spring Harbor just a few months later:
We have been engaged in a historic adventure.  Whether
your metaphor is Neil Armstrong or Lewis and Clark, your
metaphor is at risk of falling short. There is no question that
the enterprise we  have gathered here to discuss will change
our concepts of human biology, our approach to health and
disease, and our view of ourselves. This is the moment, the
time when the majority of the human genome sequence,
some 85 per cent of it, looms into view. You will remember
this. You will tell your future graduate students, perhaps
even your future grandchildren, that you sat, stood, or
sprawled in Grace Auditorium, in the presence of the intel-
lectual giants of genomics that ﬁll this hall right now, and of
Jim Watson himself, and reﬂected upon this astounding time
in our history.  (emphasis added)6 . 2 0 1 4;3 2(2):158–163
Although the genome quest is to cure all diseases and
lengthen life, there is one constellation of diseases that out-
ranks all others, as President Clinton suggested: cancer. Nor
was Clinton alone in highlighting cancer at the 2000 White
House ceremony. In the only speciﬁc case he talked about,
Francis Collins described attending the funeral of “my beloved
sister-in-law” (the day before) who “died much too soon of
breast cancer.” He continued, “The hope and promise of under-
standing all of the genes in the genome and applying this
knowledge to the development of powerful new tools came
just too late for her.” 5 Craig Venter, in his presentation, went
further, noting that the genome sequence represented a “new
starting point for science and medicine” with the potential to
impact every disease. But cancer was the disease on his mind:
. . .each day approximately 2,000 die in America from can-
cer. As a consequence of the genome efforts.  . . and the
research catalyzed by this information, there’s at least the
potential to reduce the number of cancer deaths to zero
during our lifetimes.5
It was, of course, Richard Nixon who launched America’s
“war on cancer” more  than 40 years ago. A decade after the
White House genome ceremony, Francis Collins has begun
the process of modifying the military war on cancer metaphor
described so well by Susan Sontag, to a less ambitious police
metaphor:
Coming like a thief in the night, this culprit [cancer] regularly
steals away hopes for a long and happy life. . .But the effort
to catch and convict the culprits is rapidly gaining ground.
The ability to search the genome for both hereditary and
acquired mutations provides us with an increasingly pre-
cise picture of how these ‘genes gone bad’ carry out their
dastardly deeds. And learning their MO provides us with the
opportunity to thwart their attacks in much more  effective
ways, including efforts to prevent the crime rather than try-
ing to clean up the mess afterward. . . .‘law and order’ is now
a real possibility. (emphasis supplied) 6
In her best-selling novel, State of Wonder (2011), set in
Minneapolis and Brazil, Ann Patchett also adopts the quest
metaphor, sending her female hero to the remote Amazon jun-
gle to retrieve a precious prize: a drug that would keep ovaries
young for a lifetime, and thus permit child bearing at any age.
How precious this prize is can be debated, but the historical
exploitation of “native” populations for medicines that will
beneﬁt only the rich of the world is nothing new. Although it
plays no role in the novel, it is worth noting that the US  has
impinged on Brazil in other ways as well—its companies per-
suading Brazilians who need their extremely expensive drugs
to sue the government to pay the US companies for them
under Brazil’s “right to health.”
The  Little  Prince’s  Anti-Quest
Collins also deploys stories (in the science ﬁction genre) to
help explain both why the quest for personalized medicine is
slower than he, Venter, and Clinton had predicted, and what
the future could still hold should he continue the quest. For
example, he concludes his 2009 book, The Language of Life,  with
a chapter entitled “A Vision for the Future.” In it he twice
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uotes Antoine de Saint-Exupery, the author of The Little Prince
which Collins says is “one of my  favorite books when I was
 child”), “As for the future, your task is not to foresee, but to
nable it.” 6 But the stories he tells are of most interest. The
rst story is about a little girl named Hope who was born on
ew Year’s Day, 2000. When she was 20, her favorite uncle
ied at age 48 of a heart attack. Hope decided to do a complete
amily history, supplemented with a complete genome analy-
is (which cost only $300 in 2020). With the assistance of her
hysician, she learned she was a carrier for cystic ﬁbrosis (CF),
nd was a higher risk than average for breast cancer and high
lood pressure, and at three times the normal risk of a heart
ttack. These ﬁndings motivated her to pay more  attention to
iet and exercise.
Five years later she met  George, who after their engage-
ent agreed to have his own genome analyzed. He was normal
or CF, but at higher risk for obesity and colon cancer. When,
hree years later, they decided to start a family, they did not
mploy preimplantation genetic diagnosis (PGD), but did have
 complete genome screen done on their newborn son, Ray-
ond, aka “Ray of Hope.” Ray turned out to be extremely
redisposed to obesity (60% probability), and a speciﬁc diet
ith reduced fats and calories was designed for him. By 2035
all three members of this little nuclear family were doing
ell.” In 2045 George underwent an exam for colon polyps,
hich were found and removed. “As the years passed, the
otential for extending the human life span grew. Hope and
eorge began to explore the possibility of taking a new drug
hat had just been approved for that purpose.”6
When Hope was 68 she had a heart attack; but the EMT
ho  responded to the emergency call was able to immedi-
tely institute “the proper drug treatment” to save her life
ecause he had access to her genome sequence. The follow-
ng year George, now 70, developed early signs of Parkinson
isease. His physicians used one of his skin cells to grow new
euronal cells to insert into his brain to reverse the disease.
n 2100 Hope celebrated her hundredth birthday and she and
eorge their 75th wedding anniversary with their family wish-
ng them “well for many  more  years to come.”6
This “dream” scenario is immediately contrasted to a
nightmare” scenario, in which little patient educational
aterial is available and genomic screening is discouraged, so
othing is done after her uncle dies of a heart attack. Hope still
eets George and they have a son; but he is seriously obese
y age 6 and remains so the rest of his life. Hope herself devel-
ps hypertension by age 35. When she has her heart attack
t age 50, it goes unrecognized in the emergency department
nd she dies. Her son is now morbidly obese, and George is
naware that his undiagnosed colon cancer is about to spread
o his liver. Collins concludes:
What a grim scenario! Sadly for us all, this disappointing
outcome could still happen. Yes, medical science, built upon
ever-increasing knowledge of the human genome, is poised to
deliver substantial medical beneﬁts in the coming years. Good
science is necessary but not sufﬁcient—it will take the
full engagement of researchers, governments, health care
providers, and the general public to avoid this depressing
alternative. (emphasis supplied)6 0 1 4;3 2(2):158–163 161
The book ends with a two paragraph “ﬁnal exhortation.”
The ﬁrst paragraph begins by repeating the quotation by Saint-
Exupery: “As for the future, your task is not to foresee, but to
enable it.” This is followed by a plea to readers to help enable
his personalized medicine quest: “For the future of person-
alized medicine, this exhortation is not just for the scientiﬁc
community, or the medical community, or the government—it
is for each of us. The success of personalized medicine will
come about only when we each take responsibility for our
health.” 6
Using Saint-Exupery’s The Wisdom of the Sands as a guide
to medical research is a surprise. The book is a strange and
rambling meditation on life and leadership by an imaginary
king of a desert empire. What the king means by “enabling
the future” is to ignore it, and work only in the present. The
king explains himself in the paragraph before the quotation:
Then, you may ask me, whereto must I shape my
course—since goals are meaningless? And I would answer
you by imparting that pregnant secret, hidden under sim-
ple, common words, which I have learned little by  little in
the course of my  life: to wit, that preparing the future is
but establishing the present. Those who are forever pursing
phantoms of the mind, bred of their imagination, do but fritter
themselves away in utopian dreams and vain conceits. For the
true use of the future is to decipher the present. . . (empha-
sis supplied)7
This view can be seen as an anti-quest view—instead of
working toward some imagined, wonderful future, the goal
is to concentrate solely on the present. Or, as Saint-Exupery
puts it himself (more eloquently and directly): “. . .all true cre-
ation is not a prejudgment of the Future, not a quest of utopian
chimeras, but the apprehending of a new aspect of the Present,
which is a heap of raw materials bequeathed by the Past. . .”7
The major metaphor Saint-Exupery himself uses is that of
a gardener who “enables the future” by planting seeds and
tending to his garden.
Collins may be on ﬁrmer ground with his illusion to The
Little Prince,  which is much better known and is an explicit
work of the imagination.8 Without, I think, falling victim to
my own imagination, we  can see the little prince’s request to
the narrator to “Draw me  a sheep” as a demand to enable the
future by creating something in the present. In the story the
little prince is not happy with any of the pictures the narrator
draws (just as the grownups were never happy with the
drawings he made when he was a child). Instead, it is only
when the narrator draws a box and tells the little prince
that his sheep is inside of it that the little prince is satisﬁed:
“That’s just the kind I wanted.”9
Perhaps we are like Goldilocks tasting porridge, and search-
ing for one that is not too hot, not too cold, but “just right.”
Unlike Goldilocks, however, we know at some level that we
will never ﬁnd what we are searching for, but nonetheless
believe that the quest itself is intrinsically worthwhile. Or, as
the fox tells the little prince in words that could be applied to
the leader of the human genome project: “Anything essential
is invisible to the eyes. . .It’s the time you spend on your rose
that makes your rose important.”10 This, of course, reﬂects
a hyper-individual view of medicine—and seems to ignore
population-based public health completely. Can personalized
b l i c a162  r e v p o r t s a ú d e p ú 
medicine (aka genomic-based medicine) be reconciled with
public health?
What  about  people  who  need  health  care?
The quest for personalized medicine will mean little to most
Americans if we  are unable to radically reform our health
care system, ﬁrst by making it available to all, and secondly
by controlling costs. The “quest” for a robust national health
insurance scheme with access for all has been painful.11 The
results, as passed in legislation known as the Affordable Care
Act (ACA), are still in doubt, especially following the oral
arguments at the US Supreme Court regarding the law’s consti-
tutionality in March 2012. At the argument it became clear that
at least ﬁve of the Justices wanted the US to suggest a “limiting
principle” that would allow the Court to ﬁnd the Act consti-
tutional under the Commerce Clause, but would not commit
the Court to ﬁnding any other federal requirement that Amer-
icans purchase a private product. The argument, including
appeals to slippery slopes leading to mandatory purchases
of broccoli, cell phones, burial insurance, and even certain
kinds of automobiles, was more  illuminating in showing com-
mitment to the market as a solution to health insurance
coverage than any legal principles. The government’s con-
stitutional arguments were just too abstract to defend the
constitutional challenge to the ACA. A clear limiting princi-
ple is what the Justices wanted, and it was a mistake not
to provide one in the administration’s briefs (this mistake
spelled doom for the administration’s reliance on the Com-
merce Clause, but the ACA was ultimately saved on another
ground, the federal tax authority). In the absence of a lim-
iting principle, the uniqueness of the American health care
system could be argued best, I think, by illustrating the neg-
ative impact of the current dysfunctional health care system
on the lives of tens of millions of Americans, and explaining
how the mandate makes guaranteed issue of health insur-
ance (regardless of existing health problems) possible, and
thus will change their lives for the better. In short, what
may have been needed to make the quest for a national
health insurance scheme successful (at least for now) is sto-
ries.
In electoral politics this is, of course, not controversial.
Both President Obama and then Senator Hillary Clinton,
for example, recognized the power of individual stories
of people whose lives had been dramatically and nega-
tively affected by our current nonsystem on the campaign
trail.2 And after his election, President Obama continued
to rely on the stories of real people, including his mother
and grandmother, to support the ACA.12 It is even fair to
say that the law, which just barely survived Congress and
the Supreme Court, would not have been passed at all
were it not for the stories told at a White House sum-
mit  on healthcare hosted by the President. At the summit,
stories of individuals and their often heartbreaking inter-
actions with the health care insurance industry greatly
outweighed more  abstract arguments about cost and “social-
2ized medicine.”
Appellate courts are not supposed to care; but in this case
at least an attempt should be made to convince them. And
Solicitor General Donald Verrilli ﬁnally did on the third day or . 2 0 1 4;3 2(2):158–163
oral arguments when he made the point I think he could have
usefully led with. In his words, focusing on the population of
America rather than on individuals, the ACA solves “problems
in the economic marketplace that have resulted in millions
of people not having health care because they can’t afford
insurance.” Verrilli continued, echoing the health and human
rights mantra (that health and human rights are “inextricably
linked”) in a country without a “right to health”:
There is an important connection, a profound connec-
tion between that problem and liberty. And I do think it’s
important that we not lose sight of that. . . [because of the
Medicaid expansion] there will be millions of people with
chronic conditions like diabetes and heart disease, and as a
result of the health care they will get, they will be unshack-
led from the disabilities that those diseases put on them
and have the opportunity to enjoy the blessings of liberty.
And the same will be true for the husband whose wife
is diagnosed with breast cancer and who  won’t face the
prospect of being forced into bankruptcy to try to get care
for his wife and face the risk of having to raise his chil-
dren alone, and I can multiply example after example after
example.13
The Solicitor General then aptly and succinctly summa-
rized the administration’s case that healthcare is unique, and
upholding the ACA does require granting Congress unlimited
power (the kind that the states have under their “police pow-
ers”) to regulate Americans under the Commerce Clause. How
to deal with the national problem of 50 million people with
very limited access to healthcare because they have no health
insurance is, he concluded, “a judgment of policy that [non-
elected, unaccountable, and way right of center, left unsaid]
should respect.”13
The Solicitor General may well have tried to drag the tens
of millions of uninsured Americans before the Court in an
act of desperation. Although ﬁve of the Justices continue to
believe that health care is a private market good, and not a
public good, Justice Roberts nonetheless was willing to view
the penalty provisions of the ACA as a tax and thus lead a
5 to 4 majority to uphold the mandatory health insurance
provisions in the law. Nonetheless, he also viewed the expan-
sion of Medicaid to cover all uninsured poor people as a
step too far, ruling that this provision had to be voluntary
with each state. Population health care coverage remains a
work in progress and its outcome is not predicable at this
point. Nonetheless, we can still contemplate the future of
genomics as applied to the health of the population of the
US.
Competing  quests  in  genomics
It is too soon to tell how either the quest for personalized
medicine or the quest for a universal health insurance pro-
gram will fare in the US. It is not too soon to predict the future
if it is “enabled” with successes of both of these quests. The
future these twin developments will enable is one in which
healthcare costs become the central issue in American health-
care, because by deﬁnition using an individual’s genome to
customize treatment, especially in the realm of cancer (from
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hich 160,000 Americans continue to die annually), will be
rushingly expensive.3,14
The dream that even though such treatment will be in
he hundreds of thousands of dollars it could turn out to
e cheaper than current ineffective radiation, surgery, and
hemotherapy seems a complete fairy tale, at least for now.9,14
o the extent that genomics will make healthcare less and
ess affordable than it is today, it is more  likely that only the
ealthy will be able to have access to increasingly expen-
ive drugs and procedures. Public health may make use of
enomics—but probably only as inexpensive screening tests.
ow genomics “ﬁts” is still a work in progress. With whole
enome sequencing plummeting in price, there is no doubt
hat more  and more  (millions) of people will have their
enomes screened at the recommendation of their personal
hysician. The difﬁcult decisions will not only involve adults
because genomic is probabilistic, heavily dependent on other
epigenetic” factors, and reveals private information not just
bout the individual, but about their siblings, parents, and
hildren). The much more  difﬁcult genomic screening deci-
ions involve fetuses, newborns, and children. Already there
s a serious proposal from the American College of Medical
enetics and Genomics for labs to do routine multi-genetic
creening of children and adults whenever any particular
enetic marker is tested. Similarly, Evans et al. have proposed
sing “public health genomics” to “identify those millions of
ndividuals who  unknowingly carry mutations that confer a
ramatic predisposition to preventable diseases.” How such
iseases will be selected for inclusion in population screening,
nd what the individuals who  are identiﬁed can actually do
o decrease their risk (at least other than diet and exercise)
emains to be worked out.
Nonetheless, the bioethics challenge is real: can autonomy
and informed consent) survive the genomic era? Likewise,
he human rights vision is clear: will the beneﬁts of genomics
e available to all, or only to those who  can afford to pay for
hem with private funds? As James Evans himself has put it,
ore  than 5 years ago, depriving the poor (in any country)
f personalized genomic medicine “runs the risk of creating
 genetically deﬁned underclass which, because of inherit-
ng more  than a fair share of disease-susceptibility genes, is
nable to afford adequate medical care.”15
1
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